BIO Asia–Taiwan 2022 亞洲生技大會

BIO Asia–Taiwan 2022 亞洲生技大會

TEACHER

John Lambert

Session 12 – Biologics Product Development and Manufacturing

Date:29 July (Friday)
Time:  10:40 – 12:10 (GMT+8)

John Lambert

Consultant/Scientific Advisor  (including to ImmunoGen, Inc.)
Honorary Professor, Queen’s University Belfast, Northern Ireland, UK & Consultant

 

 

 
Dr. Lambert graduated from Christ’s College, University of Cambridge (England, UK), with a degree in Natural Sciences in 1972. He then earned a Ph.D. in Biochemistry from the University of Cambridge in 1976, working on the structure of glycolytic enzymes under the supervision of Professor Richard N. Perham.

Dr Lambert’s postdoctoral training was at the University of California, Davis (1976-1980), working on ribosome structure in the laboratory of Dr Robert R. Traut, and at the University of Glasgow, Scotland, UK (1980-1982), working on the arom multienzyme complex in the laboratory of Dr John R. Coggins. 

In 1982, Dr. Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School, as the second scientist recruited to work on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics.  

Dr. Lambert joined ImmunoGen in 1987 when the company established independent research laboratories in Cambridge, Massachusetts.  After working in a variety of roles at the company, Dr. Lambert served as Chief Scientific Officer from 2008 until 2015. In 2016, he became a Distinguished Research Fellow at the company until his retirement at the end of 2017. He served on the Executive Committee of the company as Executive Vice President, Research, from 2008 until 2016. 

During Dr Lambert’s tenure in leadership roles at ImmunoGen, scientists at the company invented the ADC technology that ultimately resulted in the Genentech/Roche drug, Kadcyla® (approved in 2013 for treating HER2+ breast cancer), as well as numerous other ADCs taken into clinical development.  One of these is ImmunoGen’s mirvetuximab soravtansine, an ADC under regulatory review (BLA) by FDA for the treatment of folate receptor alpha-positive, platinum-resistant ovarian cancer.

Dr Lambert is the author/co-author of over 125 peer-reviewed scientific publications. In 2016, Dr Lambert was elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).  In 2018, he was appointed to an Honorary Professorship at Queen’s University Belfast, Northern Ireland, UK.

John M. Lambert, Ph.D.
Honorary Professor, Queen’s University Belfast, UK
Consultant/Scientific Advisor
Cambridge, MA 02139, USA

 

Speech title & Synopsis

Antibody Drug Conjugates (ADCs): 
Decades of study, successful product developments and a resurgence of interest

.
​​